Do you foresee any added benefit of triple agonist therapy (GLP-1, GIP and glucagon) for glycemic control in patients with Type 1 diabetes mellitus?

This is an interesting question. Since glucagon receptor therapy has not been tested in type 1 diabetes, let me address your question based on what we know of the physiology. Isolated glucagon receptor agonism increases hepatic glucose production and causes hyperglycemia. However, glucagon receptor ...

There are a number of triple agonists under development. Furthest along is retatrutide with average weight loss approaching 30% in the setting of obesity. GLP-1 receptor agonists have definitively demonstrated weight loss benefits in people living with type 1 diabetes. Glycemic benefits have emerged...

This is actually a speculative question, given that there is no available data to address this. But what data do we have that might inform a decision to use a triple agonist in the T1DM patient population? A recent NEJM Evidence article (Shah et al., PMID 40550013) looked at the use of semaglutide, ...